Objective: To evaluate the efficacy and symptom scores of early diabetic nephropathy (DKD) treated with modified Shenqi Dihuang Decoction. Methods: 82 patients with early DKD who visited the hospital from February 2023 to February 2025 were randomly divided into two groups by drawing. Group A received modified Shenqi Dihuang Decoction + SGLT2 inhibitor, while Group B received SGLT2 inhibitor only. The efficacy, symptom scores, blood glucose, and renal function were compared between the two groups. Results: The efficacy of Group A was higher than that of Group B in the treatment of early DKD (P < 0.05). The DKD symptom scores of Group A were lower than those of Group B (P < 0.05). The fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG), and glycated hemoglobin (HbA1c) of Group A were better than those of Group B (P < 0.05). The serum creatinine (SCr), blood urea nitrogen (BUN), and urinary albumin excretion rate (UAER) of Group A were also better than those of Group B. Conclusion: The combination of modified Shenqi Dihuang Decoction and SGLT2 inhibitor dapagliflozin has excellent efficacy in the treatment of early DKD, which can improve renal function, reduce DKD symptoms, and stabilize blood glucose levels.
Lyu C, Zheng S, Jia X, et al., 2021, The Effect of Modified Shenqi Dihuang Decoction on Blood Glucose and Urinary Protein in Patients With Early Diabetic Nephropathy. Western Journal of Traditional Chinese Medicine, 34(9): 51–53.
Microvascular Complications Study Group of the Chinese Diabetes Society, 2019, Chinese Clinical Guidelines for the Prevention and Treatment of Diabetic Kidney Disease. Chinese Journal of Diabetes, 11(1): 15–28.
Hou R, Hu W, Dong P, et al., 2022, The Effect of Modified Shenqi Dihuang Decoction Combined With ACEI/ARB in the Treatment of Patients With Diabetic Nephropathy Stages III–IV and Its Regulatory Mechanism on Proteinuria and Nrf2 Signaling Pathway. Journal of Difficult and Complex Cases, 21(6): 613–618.
Shi J, Zheng J, 2022, Clinical Observation of Modified Shenqi Dihuang Decoction Combined With ACEI/ARB in the Treatment of Diabetic Nephropathy Stages III–IV. Journal of Practical Traditional Chinese Medicine, 38(11): 1934–1937.
Xu L, 2022, Clinical Observation of Modified Shenqi Dihuang Decoction in the Treatment of Diabetic Nephropathy With Collateral Stagnation Syndrome. Guangming Journal of Chinese Medicine, 37(18): 3277–3279.
Zhao W, Wang C, Ge Y, 2023, The Effect of Modified Shenqi Dihuang Decoction in the Treatment of Stage III Diabetic Nephropathy With Tubular Injury (Qi and Yin Deficiency Syndrome) and Its Influence on Renal Function and Renal Fibrosis–Related Growth Factors. Chinese Journal of Ethnomedicine and Ethnopharmacy, 29(11): 5–7.
Li J, Li A, 2023, The Effect of Modified Buyang Huanwu Decoction Combined With Shenqi Dihuang Decoction on Oxidative Stress and Endothelial Function in Patients With Diabetic Nephropathy. Modern Journal of Integrated Traditional Chinese and Western Medicine, 32(18): 2591–2594.
Zhang Y, Zeng Z, Liu D, et al., 2022, The Clinical Effect of Yiqi Yangyin Therapy in the Treatment of Type 2 Diabetic Nephropathy (Early Stage) and Its Effect on Serum β2–MG. Inner Mongolia Journal of Traditional Chinese Medicine, 41(10): 22–24.
Wang Y, Yang F, Ma Y, et al., 2023, The Clinical Efficacy of Modified Buyang Huanwu Decoction Combined With Shenqi Dihuang Decoction in the Treatment of Stage III–IV Diabetic Nephropathy and Its Protective Effect on Renal Tubular Injury. Chinese Herbal Medicine, 54(16): 5289–5295.
Bai L, Guo S, Chen Y, et al., 2024, The Efficacy of Modified Shenqi Dihuang Decoction Combined With Taohong Siwu Decoction in the Treatment of Stage III–IV Diabetic Kidney Disease and Its Effect on Oxidative Stress. Modern Journal of Integrated Traditional Chinese and Western Medicine, 33(6): 772–777.